// 英文语言包
module.exports = {
  more:'More',
  topBar:[
    {
      id: 0,
      name: 'About'
    },
    {
      id: 1,
      name: 'Structure'
    },
    {
      id: 2,
      name: 'Invited Speakers'
    },
    {
      id: 3,
      name: 'Agenda'
    }
  ],
  topBarJson:[
    {
      id: 0,
      name: 'About'
    },
    {
      id: 1,
      name: 'Structure'
    },
    {
      id: 2,
      name: 'Invited Speakers'
    },
    {
      id: 3,
      name: 'Agenda'
    },
    {
      id: 4,
      name: 'Previous Speakers'
    },
    {
      id: 5,
      name: 'Register'
    },
    {
      id: 6,
      name: 'Associated Media'
    },
    {
      id: 7,
      name: 'Contact Us'
    }
  ],
  bigTitle:'2019 Shenzhen IBII & DS',
  jshao:{
    title:'Focus on the New Biological Economy and Innovate for the Greater Bay Area',
    text1:'In order to implement the spirit of the 9th meeting of the Central Commission of Comprehensively Deepening Reform, to support Shenzhen in building a leading demonstration area of socialism with Chinese characteristics, and to seize the important opportunity of developing the Guangdong-Hong Kong-Macao Greater Bay Area, the People’s Government of Pingshan, Shenzhen and Shenzhen branch of the China Council for the Promotion of International Trade will jointly host “the 2019 Shenzhen International Biopharmaceutical Industry Innovation & Development Summit”.',
    text2:'The summit is an exchange and exposition event in the academic, industrial and investment fields of the domestic and foreign biopharmaceutical industry, at which new paths for cooperation among Guangdong, Hong Kong and Macao will be explored by highlighting the development trend of the international biopharmaceutical industry, focusing on the innovation of the biopharmaceutical industry in the Greater Bay Area, and analyzing in depth the new direction of industrial innovation.',
    text3:'On September 12, the summit will be held in Pingshan High-tech Development Zone, Shenzhen, a core component and important strategic node of the Greater Bay Area and the Guangzhou-Shenzhen-Hong Kong Innovation Belt, where one of the first batch of national biology industrial bases in China is located, gathering over 353 biotechnology enterprises. The summit will bring together nearly 1,000 experts, including Nobel laureates, academicians at home and abroad, scientists, and those from venture capitals, innovative research teams, top 500 biopharmaceutical enterprises, and government regulatory agencies of various countries. They will get together with local entrepreneurs and experts in Pingshan, to discuss new technologies, new developments, new models, international technology transfer, achievement transformation, and financial incentives in the new policy on medicine, new drug research and development, clinical research, technological innovation and other fields.'
  },
  structure:{
    title:'Structure',
    mTitle1:'Hosted by:',
    mText1:{
      desc1:'The People’s Government of Pingshan District, Shenzhen',
      desc2:'China Council for the Promotion of International Trade, Shenzhen'
    },
    mTitle2:'Organized by:',
    mText2:{
      desc1:'Investment Promotion Bureau of Pingshan, Shenzhen',
      desc2:'Pingshan District Science and Technology Innovation Bureau, Shenzhen',
      desc3:'Pingshan District Industry and Information Technology Bureau, Shenzhen',
      desc4:'China Chamber of International Commerce Shenzhen Branch'
    }
  },
  gustTitle:"Invited Speakers",
  gustA:[
    {
      "index": 1,
      "main": [
        {
          "id": 1,
          "active": false,
          "name": "Aaron Ciechanover",
          "title": "Dr. Aaron Ciechanover is now the dean of Ciechanover Institute of Precision and Regenerative Medicine, the Chinese University of Hong Kong, Shenzhen.",
          "desc": "<p>Dr. Aaron Ciechanover, an Israel biologist and chemist, is the first Israeli who won the Nobel prize for Science. He is also a member of Israel Academy of Sciences and Humanities, foreign associate of USA National Academy of Sciences, foreign academician of Chinese Academy of Sciences, outstanding professor of Chinese University of Hong Hong, Shenzhen, honorary professor of Nanjing University, and the director of Institute of Chemistry and BioMedical Sciences of Nanjing University</p><p>In 2004, he, together with Avram Hershko, another Israeli scientist, and Irwin Rose, an American scientist, won the Nobel Prize in Chemistry for the discovery of ubiquitin-mediated protein degradation.</p><p>Dr. Aaron Ciechanover is now the dean of Ciechanover Institute of Precision and Regenerative Medicine, the Chinese University of Hong Kong, Shenzhen.</p>"
        },
        {
          "id": 2,
          "active": false,
          "name": "Mr. Li Qing",
          "title": "Mr. Li Qing, Director of Development Center for Medical Science & Technology, National Health Commission of the People’s Republic of China",
          "desc": "<p>He is currently in charge of the preparation of the 12th Five-Year Plan for Medical Technology Development, and assists the organization and implementation work of two state key technological projects “Key New Medicine Development” and “Research in Major Infectious Diseases”. He launched public health industry scientific research projects in 2010 and 2011, and organized the promotion work for public health technologies. He is also in charge of the management and coordination of continuous tele-education in the healthcare industry and relevant works in Office for Healthcare Teaching Material Management, as well as providing intermediary service for the medical industry.</p>"
        },
        {
          "id": 3,
          "active": false,
          "name": "Tan Tieniu",
          "title": "Dr. Tan Tieniu, Deputy Director of Liaison Office of the Central People’s Government in the Hong Kong S.A.R., Academician of Chinese Academy of Science, Fellow of Royal Academy of Engineering.",
          "desc": "<p>PhD. of Image Processing, Electricity and Electronic Engineering, Imperial College London, Academician of Chinese Academy of Science, Fellow of Royal Academy of Engineering, Fellow of the World Academy of Sciences and Brazilian Academy of Sciences.</p><p>Currently takes the position as Deputy Director of Liaison Office of the Central People’s Government in the Hong Kong S.A.R., Researcher and Doctoral Supervisor of Institute of Automation of Chinese Academy of Sciences, Director of the Center for Research on Intelligent Perception and Computing.</p><p>Research Field: His main researches are image processing, computer vision, pattern recognition and other related fields. His current researches involve biometrics, image & video understanding and information safety. His research fields are computer visual monitoring on dynamic scenario, people recognition and authentication based on human behavior and biometric, watermarking of digital multimedia data, etc.</p>"
        }
      ]
    },
    {
      "index": 2,
      "main": [
        {
          "id": 4,
          "active": false,
          "name": "Shi Yigong",
          "title": "Academician of Chinese Academy of Sciences, member of USA National Academy of Sciences, and president of Westlake University",
          "desc": "<p>Graduated from Tsinghua University as bachelor in 1989 and obtained Ph.D from the Johns Hopkins University in 1995. Dr. Shi is a structural biologist, professor of Tsinghua University, academician of Chinese Academy of Sciences, fellow of European Molecular Biology Organization, foreign associate of National Academy of Sciences, and academician of American Academy of Arts and Sciences. In 2017, he was awarded with the Life Science Award in the 2nd Future Science Prize. He was once a vice president of Tsinghua University.</p><p>Vice Chairman of the 9th National Committee of China Association for Science and Technology; president of Westlake University</p><p>In December 2018, Dr. Shi was elected into the list of “40 Returnees of China’s 40 Years of Reform and Opening-up”.</p><p>Research Field: His major research involves two fields, apoptosis and membrane proteins. He has made profound contribution to the control mechanism of Smad-mediated regulation of TGF pathway as well as the structural biology of PP2A.</p>"
        },
        {
          "id": 28,
          "active": false,
          "name": "Rao Yi",
          "title": "Dr. Rao Yi, current president of Capital Medical University; senior researcher & deputy academic director of National Institute of Biological Sciences, Beijing; member of Future Forum Consultation Committee; chief editor of Zhishifenzi Magazine.",
          "desc": "<p>Research Field: laboratory research in molecular signals of higher animal development, the molecular mechanism of cell migration and its application in tumor metastasis control.</p><p>Lectured Courses</p><p>Concepts and Ideas in Biology, Course master</p><p>Molecular and Cellular Neurobiology, Course master </p>"
        },
        {
          "id": 5,
          "active": false,
          "name": "Zhan Qimin",
          "title": "Academician of Chinese Academy of Sciences, and Chancellor of Peking University Shenzhen Graduate School.",
          "desc": "<p>Dr. Zhan Qimin is a professor and doctoral supervisor. He was selected to be an academician of Chinese Academy of Engineering in 2011. Currently, he is taking the position of standing member of Peking University Party Committee, vice president of Peking University, president of Peking University Health Science Center, and chancellor of Peking University Shenzhen Graduate School.</p><p>Academic Posts：Chairman of Chinese Society of Microcirculation, vice chairman of China Anti-Cancer Association, and chairman of Overseas Doctor Branch of Western Returned Scholars Association. He was once worked as the head of biology & medicine expert team and biopharmaceutical team in National High-Tech R&D Program (863 Program), the head of biomedicine expert team of National Major Project for New Drug Development, director of Scientific Technology Project Committee of National Health Commission of P.R.C, the head of National Biopharmceutical Technology Strategy Planning Expert Team, and the head of National Health Security Technology Expert Team.</p><p>Research Field:He has long been committed to research in molecular oncology and translational oncology, and discovered some systematic function and mechanism of key proteins at cell cycle checkpoints. He has also illuminated the role of multiple key cell cycle regulatory proteins in cell carcinogenesis and tumor diagnosis and individualized treatment.</p>"
        }

      ]
    },
    {
      "index": 3,
      "main": [
        {
          "id": 6,
          "active": false,
          "name": "LO Yuk Ming",
          "title": "Professor LO Yuk Ming, Dennis , Vice President of Faculty of Medicine, The Chinese University of Hong Kong; foreign associate of National Academy of Sciences (USA)",
          "desc": "<p>Professor Lo is a clinical expert in molecular biology, foreign associate of National Academy of Sciences (USA), fellow of The World Academy of Sciences, and follow of The Hong Kong Academy of Sciences. Now he is Associate Dean of Faculty of Medicine and Chairman of Department of Chemical Pathology, The Chinese University of Hong Kong, Director of Li Ka Shing Institute of Health Sciences, Professor of Chemical Pathology and the Li Ka Shing Professor of Medicine of The Chinese University of Hong Kong.<p><p>Professor Lo has spent years in researching DNA and RNA in human blood plasma, and in 1997 he found fetal DNA in maternal plasma , and later he developed an approach to accurately analyze and measure fetal DNA in maternal plasma . He is honored as the founder of noninvasive prenatal DNA testing.</p>"
        },
        {
          "id": 7,
          "active": false,
          "name": "Xu Yangsheng",
          "title": "Prof. Xu Yangsheng, Academician of the Chinese Academy of Engineering, and President of the Chinese University of Hong Kong, Shenzhen",
          "desc": "<p>Professor Xu Yangsheng is an expert on space robots and intelligent control. He is an academician of the Chinese Academy of Engineering, one of the first members of the Chinese Association for Artificial Intelligence, and chair professor of Automation and Computer-aided Engineering at the Chinese University of Hong Kong.</p><p>Since 2011, he has served as vice-president of the Chinese University of Hong Kong and is vice-president of Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. He is the president of the Chinese University of Hong Kong, Shenzhen.</p><p>In February 2019, he was appointed honorary president and director of the academic committee of the Satellite Industry Technology Research Institute, University of Electronic Science and Technology of China.</p><p>Research: Professor Xu’s research includes robotics and intelligent systems and artificial intelligence. He has made important contributions to the design, control and dynamics research of space robots and the development of gravity-free ground test facilities. He is committed to promoting the development of China’s space intelligent control technology, and has proposed and participated in the development of space intelligent systems. Meanwhile, he has conducted in-depth research on and systematic development in the control of dynamic stability systems, automatic modeling of human control strategies, wearable intelligent man-machine interfaces, and hybrid electric vehicles.</p>"
        },
        {
          "id": 8,
          "active": false,
          "name": "Wang Xiaodong",
          "title": "Fellow of National Academy of Sciences (NAS), and Director of National Institute of Biological Sciences, Beijing",
          "desc": "<p>Dr. Wang Xiaodong is a biochemist, fellow of NAS, academician of CAS, director of National Institute of Biological Sciences, Beijing, and co-founder of BeiGene.</p><p>Dr. Wang’s research focuses on the biochemical pathway and process of apoptosis.</p>"
        }
      ]
    },
    {
      "index": 4,
      "main": [
        {
          "id": 29,
          "active": false,
          "name": "Han Zhongchao",
          "title": "Dr. Han Zhongchao, foreign member of the French National Academy of Medicine and Chairman of Beijing Health-Biotech Group.",
          "desc": "<p>He was born in Shangrao, Jiangxi Province in 1953. He is a professor and doctoral supervisor of School of Medicine of Nankai University. He is also the head of Hematonosis Hospital affiliated to the Hematonosis Institute of Peking Union Medical College, a standing member of the 12th Central Committee of the Jiusan Society and a standing member of the 11th National Committee of CPPCC. In 2006, he was elected to be a foreign member of the French National Academy of Medicine. His major research involves the research and development with respect to cellular & molecular biology and bio-technologies of blood and blood vessels . His is an international leader in the research of stem cell, megakaryocyte and blood platelet, angiogenesis and its control, and chemotactic factors as well.</p>"
        },
        {
          "id": 11,
          "active": false,
          "name": "Yao Yi",
          "title": " Former Senior FDA Clinical Assessment Officer",
          "desc": "<p>Dr. Yao Yi, M.D., former senior FDA clinical assessment officer. He is currently a senior medical officer and registered doctor of U.S. Federal Government.</p>"
        },
        {
          "id": 13,
          "active": false,
          "name": "Song Ruilin",
          "title": "President of China Pharmaceutical Innovation and Research Development Association",
          "desc": "<p>Mr. Song Ruilin received his L.L.B. from China University of Political Science and Law, and EMBA from China Europe International Business School. He is the Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Executive Deputy Director of the Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University. Mr. Song was former Deputy Director-General of the Department of Education, Science, Culture and Public Health in Legislative Affairs Office at State Council of China. He has long engaged in the research of health and drug policy and law, especially in optimizing the reform of China’s drug review and approval system and medical insurance and reimbursement system and policies for pharmaceutical innovation in China. </p><p>Currently, Mr. Song also undertakes several social positions, such as Arbitrator of China International Economic and Trade Arbitration Commission (CIETAC), Standing Director of China Chamber of International Commerce (CCOIC) and Director of Chinese Pharmaceutical Association (CPA).</p>"
        }
      ]
    },
    {
      "index": 5,
      "main": [
        {
          "id": 14,
          "active": false,
          "name": "Lo Yuk Lam",
          "title": "Chairman of HK Bio-Med Innotech Association",
          "desc": "<p>Chairman of HK Bio-Med Innotech Association</p><p>“Father of Biotech in Hong Kong”</p><p>Chairman of Advisory Council on Food and Environmental Hygiene of the Food and Health Bureau of the HKSAR</p><p>Honorary Chairman of Hong Kong Biotechnology Organization </p><p>General Committee Member of The Chinese Manufacturers’ Association of Hong Kong</p><p>Chairman of the Innovation and Technology Committee of the CMA</p><p>Consultant of the Chinese Centre for Disease Control and Prevention </p><p>Member of the Advisory Committee of the Vocational Training Council </p><p>Adjunct Professor of CUHK, Fellow of HKUST, Fellow of The Hong Kong University of Science and Technology and an Honorary Professor of several universities in China</p><p>Independent director of Sinovac Biotech Limited (listed on NASDAQ)</p><p>Independent non-executive director of Luye Pharma Group Ltd. (HKSE:2186) and CSPC Pharmaceutical Group Limited (HKSE:1093)</p><p>President of Saitai Biotech Research Institute, Vice-Chairman of Santai Eco Fishery Ltd</p><p>Former Chairman of Asia Pacific, Perkin EImer</p><p>B.Sc. (The University of Waterloo), Honorary Ph.D. (York University, U.S.)</p>"
        },
        {
          "id": 15,
          "active": false,
          "name": "Li Xiaojia",
          "title": "Chief Executive of HKEX Group",
          "desc": "<p>Li Xiaojia is a prestigious banker, with almost 20 years’ experience in the legal and financial industry on Wall Street, and finance and consultation for Chinese companies. In 2009, he was appointed as Chief Executive of the HKEX group. After taking office, he has pushed through bold reforms for HKEX, including RMB IPO and the “Single Tranche, Single Counter” Model.</p>"
        },
        {
          "id": 16,
          "active": false,
          "name": "Lu Xianping",
          "title": "Director, President and Chief Scientific Officer of CHIPSCREEN BIOSCIENCES",
          "desc": "<p>One of main initiators and founders of CHIPSCREEN BIOSCIENCES. “A fighter of new drug research and development” called by insiders.</p><p>Currently, he is a member of Guangdong Provincial Expert Committee of Science and Technology, member of Shenzhen Municipal Expert Committee of Science and Technology, the head of the Biology, Medicine, Medical Devices and Environmental Protection Group, and an expert for the “863” program sponsored by the Ministry of Science and Technology.</p><p>Having considerable expertise in molecular medicine, oncology, neuroendocrinology, immunology, metabolism and skin diseases, Dr. Lu has made many important contributions in the research of nuclear hormone receptors, especially in the chemical structure design, biological and pharmaceutical activities and innovative drug development with respect to nuclear hormone receptors and ligands.</p>"
        }
      ]
    },
    {
      "index": 6,
      "main": [
        {
          "id": 17,
          "active": false,
          "name": "Tian Yuan",
          "title": "Chairman of YuanMing Capital",
          "desc": "<p>Founding PartnerCo-founder of YuanMing Capital, Chairman of Mevion Medical Systems Inc.Co., Ltd., Chairman of Yabuli China Entrepreneurs Forum, Head of Investment Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA)</p><p>Dr. Tian Yuan obtained a bachelor's degree, a master's degree and a doctorate in economics from Wuhan University respectively in 1978, 1981 and 1992. He is the co-foundera founding partner of YuanMing Capital, and chairman of the Mevion Medical Systems IncCo., Ltd. As the a founder and the chairman of Yabuli China Entrepreneurs Forum and of China-US Business Leaders Roundtable Conference, Tian is the a core organizer of various a variety of high-end conferences of Chinese and American entrepreneurs, and has a very wide social influence in the business circles of China and the United States. He is also Head of Investment Committee of PhIRDA and member of the Biotechnology Advisory Panel of the Hong Kong Stock Exchange. In 2014, he founded YuanMing Capital and took the lead in investment projects including BeiGene, Ascentage Pharma, Mevion Medical, Pharmacodia, CF PharmTech, JW Therapeutics, Adlai Nortye and Digital China HealthShenzhou China Medical Equipment. He once founded China International Futures Co., Ltd. and co-founded Wu Mart and Yabuli Ski Resort. He also served as Chairman of China Chengtong Holdings Group. He has won the China Economic Theory Innovation Award, the highest prize in China's economics.</p>"
        },
        {
          "id": 18,
          "active": false,
          "name": "Nisa Leung",
          "title": "Managing Partner of Qiming Venture Partners",
          "desc": "<p>Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She currently sits on the board of Gan & Lee Pharmaceutical, Zai Laboratories, Novast Laboratories (China) Ltd., Nurotron Biotechnology, Kunming Jiahe Science & Technology Co., Ltd., and OriGene Technologies. She also serves on the Board of Trustees of HKUST Business School, and that of the Hotchkiss School.</p><p>Nisa Leung is a managing partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages five US dollar funds and three RMB funds, with US$2.5 billion assets under management and investment in over 160 companies.</p>"
        },
        {
          "id": 19,
          "active": false,
          "name": "Liu Liang",
          "title": "President of Macau University of Science and Technology",
          "desc": "<p>Liu Liang is the president of Macao University of Science and Technology, director of the State Key Laboratory of Quality Research in Chinese Medicine, consultant of WHO’s Traditional Medicine Team, convener of the ISO/TC249/WG on Standardization of Traditional Chinese Medicine, and expert for project review specially invited by the National Natural Science Foundation.</p><p> Versed in Chinse and western medical science, Professor Liu is a well-known expert in the fields of anti-inflammatory and immune pharmacology of Chinese medicine, research and development of new drugs of Chinese medicine, rheumatism and arthritis research. He has published more than 300 papers in academic journals and conferences at home and abroad, including Nature. He also serves as editor of various English academic journals, including Journal of Chinese Evidence-based Medicine, Journal of Chinese Medicine, Chinese J of Immunology, and Journal of Materia Medica. In May 2017, he won a national innovation pioneer prize. </p>"
        }
      ]
    },
    {
      "index": 7,
      "main": [
        {
          "id": 20,
          "active": false,
          "name": "Yuan Qing",
          "title": "General Manager of Shenzhen Main Luck Pharmaceuticals Inc.",
          "desc": "<p>Yuan Qing is a senior visiting scholar of Académie des sciences, a research assistant and doctoral candidate of LMU München. He earned his doctorate in biology from McMaster University. He is listed in Shenzhen Overseas High-Level Talents (Peacock Plan), and the first High-Level Talents of Pingshan District, and has won an Award of Science and Technology of Pingshan District for technological leaders. With many papers published in PNAS, JBC, IAI and other internationally famous journals, he has also taken charge of several research projects supported by the National Health and Family Planning Commission of the People’s Republic of China, Guangdong Province and Shenzhen City. Now, He serves as Vice Chairman of Shenzhen Anti-cancer Association, and the General Manager of Shenzhen Main Luck Pharmaceuticals Inc.</p>"
        },
        {
          "id": 21,
          "active": false,
          "name": "Mr. Luo Fei",
          "title": "H50 Rotating Chairman, and Chairman of Green Pine Capital Partners",
          "desc": "<p>Mr. Luo Fei is Founding Partner, Chairman and General Manager of Green Pine Capital Partners. He also holds the post of Managing Director of Shenzhen-Hong Kong Production and Research Investment Co., Ltd., and is a delegate at the fifth People’s Congress of Shenzhen.</p><p>In 2014, he was ranked 30th among the best venture investors in China.</p><p>Major projects: Youzu.com, BGI Dx, 7Road.com, Farad Electric, Beike Biology, Rainbow Fine Chemical, Comix Group, A8 Music, CATIC Wellness Group, and Shenzhen Temobi.</p>"
        },
        {
          "id": 22,
          "active": false,
          "name": "Li Jing",
          "title": "Chairman of Pharmacodia Holding Ltd.Yaodu",
          "desc": "<p>National Chair Professor of the “1000-Plan”, Li Jing is one of the most successful entrepreneurs who returned from studying overseas. From 2006 until now, he has participated in the establishment of the following companies: Shenogen Pharma Group, Beijing Orbiepharm Co., Ltd., Pharmacodia (Beijing) Co., Ltd., and 3E Bioventures; he has published more than 30 papers, and applied for more than 50 patents. Li has also participated in and taken charge of many national projects, such as the Major Scientific and Technological Special Project for Significant New Drugs Development during the “Eleventh Five-year Plan Period”, the National Key Technology R&D Program, and Scientific Special Project of Beijing (Haidian) Municipal Science and Technology Commission, Beijing.</p>"
        }
      ]
    },
    {
      "index": 8,
      "main": [
        {
          "id": 25,
          "active": false,
          "name": "Cao Erbao",
          "title": "Research Director of the Liaison Office of the Central People’s Government in the Hong Kong Special Administrative Region, and Special Researcher of the Counsellors’ Office of the State Council.",
          "desc": "<p>Mr. Cao Erbao is a senior expert on the research of Hong Kong and Macao issues. Since his stay in Hong Kong in 1986, he has participated in the historical process of Hong Kong’s return and the practice of “One Country, Two Systems” after the return. He is familiar with the central government’s policies with respect to Hong Kong, Hong Kong’s political, business and academic circles, and other relevant people. He often gives lectures to the central and mainland departments in connection with Hong Kong, visiting delegations, Chinese enterprises, patriotic organizations, etc., and makes public speeches, publishes articles, and holds talks with the opposition in Hong Kong, all giving a great and positive impact.</p>"
        },
        {
          "id": 27,
          "active": false,
          "name": "Ir Professor Ping-kong Alexander Wai",
          "title": "Fellow of IEEE, Fellow of Optical Society of America, Fellow of the Hong Kong Academy of Engineering Science",
          "desc": "<p>Ir Professor Ping-kong Alexander Wai ( Fellow of IEEE, Fellow of Optical Society of America, Fellow of the Hong Kong Academy of Engineering Science) is Vice President (Research Development) of The Hong Kong Polytechnic University (PolyU). Professor Wai has been selected for the 'National Science and Technology Programmes Expert Database' since February 2012. Professor Wai has over 160 refereed international journal publications. He has participated in the organisation of many international conferences in photonics and optical communications such as the Conference of Laser and Electro-Optics and the Optical Fiber Communication Conference. Professor Wai is currently an Associate Editor of IEEE Journal of Lightwave Technology.</p><p>Nonlinear Optics, Fiber Lasers, Fiber Optic Communications, and Network Theory</p>"
        },
        {
          "id": 9,
          "active": false,
          "name": "Jean-Pierre Cazenave",
          "title": "Honorary Professor of Hematology and Transfusion at the University of Strasbourg",
          "desc": "<p>Honorary Professor of Hematology and Transfusion at the University of Strasbourg, Jean-Pierre Cazenave is also president of the Strasbourg medical research association ARMESA, president of the strategic committee of Health & Biotech France, and permanent member of the French National Academy of Medicine. From 1987 to 2013, he held the position of director at the Blood Transfusion Center EFS-Alsace in Strasbourg. Former president (1992-1995) and vice-president (2002-2010) of the Société Française de Transfusion Sanguine, he is currently member of several international medical societies and author of 620 scientific publications.</p>"
        }
      ]
    }
  ],
  gustB:[
    {
      "index": 1,
      "main": [
        {
          "id": 1,
          "active": false,
          "name": "Aaron Ciechanover",
          "title": "Dr. Aaron Ciechanover is now the dean of Ciechanover Institute of Precision and Regenerative Medicine, the Chinese University of Hong Kong, Shenzhen.",
          "desc": "<p>Dr. Aaron Ciechanover, an Israel biologist and chemist, is the first Israeli who won the Nobel prize for Science. He is also a member of Israel Academy of Sciences and Humanities, foreign associate of USA National Academy of Sciences, foreign academician of Chinese Academy of Sciences, outstanding professor of Chinese University of Hong Hong, Shenzhen, honorary professor of Nanjing University, and the director of Institute of Chemistry and BioMedical Sciences of Nanjing University</p><p>In 2004, he, together with Avram Hershko, another Israeli scientist, and Irwin Rose, an American scientist, won the Nobel Prize in Chemistry for the discovery of ubiquitin-mediated protein degradation.</p><p>Dr. Aaron Ciechanover is now the dean of Ciechanover Institute of Precision and Regenerative Medicine, the Chinese University of Hong Kong, Shenzhen.</p>"
        },
        {
          "id": 2,
          "active": false,
          "name": "Mr. Li Qing",
          "title": "Mr. Li Qing, Director of Development Center for Medical Science & Technology, National Health Commission of the People’s Republic of China",
          "desc": "<p>He is currently in charge of the preparation of the 12th Five-Year Plan for Medical Technology Development, and assists the organization and implementation work of two state key technological projects “Key New Medicine Development” and “Research in Major Infectious Diseases”. He launched public health industry scientific research projects in 2010 and 2011, and organized the promotion work for public health technologies. He is also in charge of the management and coordination of continuous tele-education in the healthcare industry and relevant works in Office for Healthcare Teaching Material Management, as well as providing intermediary service for the medical industry.</p>"
        },
        {
          "id": 3,
          "active": false,
          "name": "Tan Tieniu",
          "title": "Dr. Tan Tieniu, Deputy Director of Liaison Office of the Central People’s Government in the Hong Kong S.A.R., Academician of Chinese Academy of Science, Fellow of Royal Academy of Engineering.",
          "desc": "<p>PhD. of Image Processing, Electricity and Electronic Engineering, Imperial College London, Academician of Chinese Academy of Science, Fellow of Royal Academy of Engineering, Fellow of the World Academy of Sciences and Brazilian Academy of Sciences.</p><p>Currently takes the position as Deputy Director of Liaison Office of the Central People’s Government in the Hong Kong S.A.R., Researcher and Doctoral Supervisor of Institute of Automation of Chinese Academy of Sciences, Director of the Center for Research on Intelligent Perception and Computing.</p><p>Research Field: His main researches are image processing, computer vision, pattern recognition and other related fields. His current researches involve biometrics, image & video understanding and information safety. His research fields are computer visual monitoring on dynamic scenario, people recognition and authentication based on human behavior and biometric, watermarking of digital multimedia data, etc.</p>"
        },
        {
          "id": 4,
          "active": false,
          "name": "Shi Yigong",
          "title": "Academician of Chinese Academy of Sciences, member of USA National Academy of Sciences, and president of Westlake University",
          "desc": "<p>Graduated from Tsinghua University as bachelor in 1989 and obtained Ph.D from the Johns Hopkins University in 1995. Dr. Shi is a structural biologist, professor of Tsinghua University, academician of Chinese Academy of Sciences, fellow of European Molecular Biology Organization, foreign associate of National Academy of Sciences, and academician of American Academy of Arts and Sciences. In 2017, he was awarded with the Life Science Award in the 2nd Future Science Prize. He was once a vice president of Tsinghua University.</p><p>Vice Chairman of the 9th National Committee of China Association for Science and Technology; president of Westlake University</p><p>In December 2018, Dr. Shi was elected into the list of “40 Returnees of China’s 40 Years of Reform and Opening-up”.</p><p>Research Field: His major research involves two fields, apoptosis and membrane proteins. He has made profound contribution to the control mechanism of Smad-mediated regulation of TGF pathway as well as the structural biology of PP2A.</p>"
        },
        {
          "id": 28,
          "active": false,
          "name": "Rao Yi",
          "title": "Dr. Rao Yi, current president of Capital Medical University; senior researcher & deputy academic director of National Institute of Biological Sciences, Beijing; member of Future Forum Consultation Committee; chief editor of Zhishifenzi Magazine.",
          "desc": "<p>Research Field: laboratory research in molecular signals of higher animal development, the molecular mechanism of cell migration and its application in tumor metastasis control.</p><p>Lectured Courses</p><p>Concepts and Ideas in Biology, Course master</p><p>Molecular and Cellular Neurobiology, Course master </p>"
        }
      ]
    },
    {
      "index": 2,
      "main": [
        {
          "id": 5,
          "active": false,
          "name": "Zhan Qimin",
          "title": "Academician of Chinese Academy of Sciences, and Chancellor of Peking University Shenzhen Graduate School.",
          "desc": "<p>Dr. Zhan Qimin is a professor and doctoral supervisor. He was selected to be an academician of Chinese Academy of Engineering in 2011. Currently, he is taking the position of standing member of Peking University Party Committee, vice president of Peking University, president of Peking University Health Science Center, and chancellor of Peking University Shenzhen Graduate School.</p><p>Academic Posts：Chairman of Chinese Society of Microcirculation, vice chairman of China Anti-Cancer Association, and chairman of Overseas Doctor Branch of Western Returned Scholars Association. He was once worked as the head of biology & medicine expert team and biopharmaceutical team in National High-Tech R&D Program (863 Program), the head of biomedicine expert team of National Major Project for New Drug Development, director of Scientific Technology Project Committee of National Health Commission of P.R.C, the head of National Biopharmceutical Technology Strategy Planning Expert Team, and the head of National Health Security Technology Expert Team.</p><p>Research Field:He has long been committed to research in molecular oncology and translational oncology, and discovered some systematic function and mechanism of key proteins at cell cycle checkpoints. He has also illuminated the role of multiple key cell cycle regulatory proteins in cell carcinogenesis and tumor diagnosis and individualized treatment.</p>"
        },
        {
          "id": 6,
          "active": false,
          "name": "LO Yuk Ming",
          "title": "Professor LO Yuk Ming, Dennis , Vice President of Faculty of Medicine, The Chinese University of Hong Kong; foreign associate of National Academy of Sciences (USA)",
          "desc": "<p>Professor Lo is a clinical expert in molecular biology, foreign associate of National Academy of Sciences (USA), fellow of The World Academy of Sciences, and follow of The Hong Kong Academy of Sciences. Now he is Associate Dean of Faculty of Medicine and Chairman of Department of Chemical Pathology, The Chinese University of Hong Kong, Director of Li Ka Shing Institute of Health Sciences, Professor of Chemical Pathology and the Li Ka Shing Professor of Medicine of The Chinese University of Hong Kong.<p><p>Professor Lo has spent years in researching DNA and RNA in human blood plasma, and in 1997 he found fetal DNA in maternal plasma , and later he developed an approach to accurately analyze and measure fetal DNA in maternal plasma . He is honored as the founder of noninvasive prenatal DNA testing.</p>"
        },
        {
          "id": 7,
          "active": false,
          "name": "Xu Yangsheng",
          "title": "Prof. Xu Yangsheng, Academician of the Chinese Academy of Engineering, and President of the Chinese University of Hong Kong, Shenzhen",
          "desc": "<p>Professor Xu Yangsheng is an expert on space robots and intelligent control. He is an academician of the Chinese Academy of Engineering, one of the first members of the Chinese Association for Artificial Intelligence, and chair professor of Automation and Computer-aided Engineering at the Chinese University of Hong Kong.</p><p>Since 2011, he has served as vice-president of the Chinese University of Hong Kong and is vice-president of Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. He is the president of the Chinese University of Hong Kong, Shenzhen.</p><p>In February 2019, he was appointed honorary president and director of the academic committee of the Satellite Industry Technology Research Institute, University of Electronic Science and Technology of China.</p><p>Research: Professor Xu’s research includes robotics and intelligent systems and artificial intelligence. He has made important contributions to the design, control and dynamics research of space robots and the development of gravity-free ground test facilities. He is committed to promoting the development of China’s space intelligent control technology, and has proposed and participated in the development of space intelligent systems. Meanwhile, he has conducted in-depth research on and systematic development in the control of dynamic stability systems, automatic modeling of human control strategies, wearable intelligent man-machine interfaces, and hybrid electric vehicles.</p>"
        },
        {
          "id": 8,
          "active": false,
          "name": "Wang Xiaodong",
          "title": "Fellow of National Academy of Sciences (NAS), and Director of National Institute of Biological Sciences, Beijing",
          "desc": "<p>Dr. Wang Xiaodong is a biochemist, fellow of NAS, academician of CAS, director of National Institute of Biological Sciences, Beijing, and co-founder of BeiGene.</p><p>Dr. Wang’s research focuses on the biochemical pathway and process of apoptosis.</p>"
        },
        {
          "id": 29,
          "active": false,
          "name": "Han Zhongchao",
          "title": "Dr. Han Zhongchao, foreign member of the French National Academy of Medicine and Chairman of Beijing Health-Biotech Group.",
          "desc": "<p>He was born in Shangrao, Jiangxi Province in 1953. He is a professor and doctoral supervisor of School of Medicine of Nankai University. He is also the head of Hematonosis Hospital affiliated to the Hematonosis Institute of Peking Union Medical College, a standing member of the 12th Central Committee of the Jiusan Society and a standing member of the 11th National Committee of CPPCC. In 2006, he was elected to be a foreign member of the French National Academy of Medicine. His major research involves the research and development with respect to cellular & molecular biology and bio-technologies of blood and blood vessels . His is an international leader in the research of stem cell, megakaryocyte and blood platelet, angiogenesis and its control, and chemotactic factors as well.</p>"
        }
      ]
    },
    {
      "index": 3,
      "main": [
        {
          "id": 11,
          "active": false,
          "name": "Yao Yi,",
          "title": " Former Senior FDA Clinical Assessment Officer",
          "desc": "<p>Dr. Yao Yi, M.D., former senior FDA clinical assessment officer. He is currently a senior medical officer and registered doctor of U.S. Federal Government.</p>"
        },
        {
          "id": 13,
          "active": false,
          "name": "Song Ruilin",
          "title": "President of China Pharmaceutical Innovation and Research Development Association",
          "desc": "<p>Mr. Song Ruilin received his L.L.B. from China University of Political Science and Law, and EMBA from China Europe International Business School. He is the Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Executive Deputy Director of the Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University. Mr. Song was former Deputy Director-General of the Department of Education, Science, Culture and Public Health in Legislative Affairs Office at State Council of China. He has long engaged in the research of health and drug policy and law, especially in optimizing the reform of China’s drug review and approval system and medical insurance and reimbursement system and policies for pharmaceutical innovation in China. </p><p>Currently, Mr. Song also undertakes several social positions, such as Arbitrator of China International Economic and Trade Arbitration Commission (CIETAC), Standing Director of China Chamber of International Commerce (CCOIC) and Director of Chinese Pharmaceutical Association (CPA).</p>"
        },
        {
          "id": 14,
          "active": false,
          "name": "Lo Yuk Lam",
          "title": "Chairman of HK Bio-Med Innotech Association",
          "desc": "<p>Chairman of HK Bio-Med Innotech Association</p><p>“Father of Biotech in Hong Kong”</p><p>Chairman of Advisory Council on Food and Environmental Hygiene of the Food and Health Bureau of the HKSAR</p><p>Honorary Chairman of Hong Kong Biotechnology Organization </p><p>General Committee Member of The Chinese Manufacturers’ Association of Hong Kong</p><p>Chairman of the Innovation and Technology Committee of the CMA</p><p>Consultant of the Chinese Centre for Disease Control and Prevention </p><p>Member of the Advisory Committee of the Vocational Training Council </p><p>Adjunct Professor of CUHK, Fellow of HKUST, Fellow of The Hong Kong University of Science and Technology and an Honorary Professor of several universities in China</p><p>Independent director of Sinovac Biotech Limited (listed on NASDAQ)</p><p>Independent non-executive director of Luye Pharma Group Ltd. (HKSE:2186) and CSPC Pharmaceutical Group Limited (HKSE:1093)</p><p>President of Saitai Biotech Research Institute, Vice-Chairman of Santai Eco Fishery Ltd</p><p>Former Chairman of Asia Pacific, Perkin EImer</p><p>B.Sc. (The University of Waterloo), Honorary Ph.D. (York University, U.S.)</p>"
        },
        {
          "id": 15,
          "active": false,
          "name": "Li Xiaojia",
          "title": "Chief Executive of HKEX Group",
          "desc": "<p>Li Xiaojia is a prestigious banker, with almost 20 years’ experience in the legal and financial industry on Wall Street, and finance and consultation for Chinese companies. In 2009, he was appointed as Chief Executive of the HKEX group. After taking office, he has pushed through bold reforms for HKEX, including RMB IPO and the “Single Tranche, Single Counter” Model.</p>"
        },
        {
          "id": 16,
          "active": false,
          "name": "Lu Xianping",
          "title": "Director, President and Chief Scientific Officer of CHIPSCREEN BIOSCIENCES",
          "desc": "<p>One of main initiators and founders of CHIPSCREEN BIOSCIENCES. “A fighter of new drug research and development” called by insiders.</p><p>Currently, he is a member of Guangdong Provincial Expert Committee of Science and Technology, member of Shenzhen Municipal Expert Committee of Science and Technology, the head of the Biology, Medicine, Medical Devices and Environmental Protection Group, and an expert for the “863” program sponsored by the Ministry of Science and Technology.</p><p>Having considerable expertise in molecular medicine, oncology, neuroendocrinology, immunology, metabolism and skin diseases, Dr. Lu has made many important contributions in the research of nuclear hormone receptors, especially in the chemical structure design, biological and pharmaceutical activities and innovative drug development with respect to nuclear hormone receptors and ligands.</p>"
        }
      ]
    },
    {
      "index": 4,
      "main": [
        {
          "id": 17,
          "active": false,
          "name": "Tian Yuan",
          "title": "Chairman of YuanMing Capital",
          "desc": "<p>Founding PartnerCo-founder of YuanMing Capital, Chairman of Mevion Medical Systems Inc.Co., Ltd., Chairman of Yabuli China Entrepreneurs Forum, Head of Investment Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA)</p><p>Dr. Tian Yuan obtained a bachelor's degree, a master's degree and a doctorate in economics from Wuhan University respectively in 1978, 1981 and 1992. He is the co-foundera founding partner of YuanMing Capital, and chairman of the Mevion Medical Systems IncCo., Ltd. As the a founder and the chairman of Yabuli China Entrepreneurs Forum and of China-US Business Leaders Roundtable Conference, Tian is the a core organizer of various a variety of high-end conferences of Chinese and American entrepreneurs, and has a very wide social influence in the business circles of China and the United States. He is also Head of Investment Committee of PhIRDA and member of the Biotechnology Advisory Panel of the Hong Kong Stock Exchange. In 2014, he founded YuanMing Capital and took the lead in investment projects including BeiGene, Ascentage Pharma, Mevion Medical, Pharmacodia, CF PharmTech, JW Therapeutics, Adlai Nortye and Digital China HealthShenzhou China Medical Equipment. He once founded China International Futures Co., Ltd. and co-founded Wu Mart and Yabuli Ski Resort. He also served as Chairman of China Chengtong Holdings Group. He has won the China Economic Theory Innovation Award, the highest prize in China's economics.</p>"
        },
        {
          "id": 18,
          "active": false,
          "name": "Nisa Leung",
          "title": "Managing Partner of Qiming Venture Partners",
          "desc": "<p>Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She currently sits on the board of Gan & Lee Pharmaceutical, Zai Laboratories, Novast Laboratories (China) Ltd., Nurotron Biotechnology, Kunming Jiahe Science & Technology Co., Ltd., and OriGene Technologies. She also serves on the Board of Trustees of HKUST Business School, and that of the Hotchkiss School.</p><p>Nisa Leung is a managing partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages five US dollar funds and three RMB funds, with US$2.5 billion assets under management and investment in over 160 companies.</p>"
        },
        {
          "id": 19,
          "active": false,
          "name": "Liu Liang",
          "title": "President of Macau University of Science and Technology",
          "desc": "<p>Liu Liang is the president of Macao University of Science and Technology, director of the State Key Laboratory of Quality Research in Chinese Medicine, consultant of WHO’s Traditional Medicine Team, convener of the ISO/TC249/WG on Standardization of Traditional Chinese Medicine, and expert for project review specially invited by the National Natural Science Foundation.</p><p> Versed in Chinse and western medical science, Professor Liu is a well-known expert in the fields of anti-inflammatory and immune pharmacology of Chinese medicine, research and development of new drugs of Chinese medicine, rheumatism and arthritis research. He has published more than 300 papers in academic journals and conferences at home and abroad, including Nature. He also serves as editor of various English academic journals, including Journal of Chinese Evidence-based Medicine, Journal of Chinese Medicine, Chinese J of Immunology, and Journal of Materia Medica. In May 2017, he won a national innovation pioneer prize. </p>"
        },
        {
          "id": 20,
          "active": false,
          "name": "Yuan Qing",
          "title": "General Manager of Shenzhen Main Luck Pharmaceuticals Inc.",
          "desc": "<p>Yuan Qing is a senior visiting scholar of Académie des sciences, a research assistant and doctoral candidate of LMU München. He earned his doctorate in biology from McMaster University. He is listed in Shenzhen Overseas High-Level Talents (Peacock Plan), and the first High-Level Talents of Pingshan District, and has won an Award of Science and Technology of Pingshan District for technological leaders. With many papers published in PNAS, JBC, IAI and other internationally famous journals, he has also taken charge of several research projects supported by the National Health and Family Planning Commission of the People’s Republic of China, Guangdong Province and Shenzhen City. Now, He serves as Vice Chairman of Shenzhen Anti-cancer Association, and the General Manager of Shenzhen Main Luck Pharmaceuticals Inc.</p>"
        },
        {
          "id": 21,
          "active": false,
          "name": "罗飞",
          "title": "H50轮值主席，松禾资本董事长",
          "desc": "<p>罗飞，松禾资本创始合伙人、董事长兼总经理，兼任深港产学研创业投资有限公司董事总经理、深圳市第五届人大代表。</p><p>2014年位列年度中国最佳创业投资人第30名。</p><p>代表项目：游族网络、华大医学、第七大道科技、华力特电气、北科生物、彩虹精化、齐心文具、A8音乐、中航健身时尚、融创天下</p>"
        }
      ]
    },
    {
      "index": 5,
      "main": [
        {
          "id": 22,
          "active": false,
          "name": "Li Jing",
          "title": "Chairman of Pharmacodia Holding Ltd.Yaodu",
          "desc": "<p>National Chair Professor of the “1000-Plan”, Li Jing is one of the most successful entrepreneurs who returned from studying overseas. From 2006 until now, he has participated in the establishment of the following companies: Shenogen Pharma Group, Beijing Orbiepharm Co., Ltd., Pharmacodia (Beijing) Co., Ltd., and 3E Bioventures; he has published more than 30 papers, and applied for more than 50 patents. Li has also participated in and taken charge of many national projects, such as the Major Scientific and Technological Special Project for Significant New Drugs Development during the “Eleventh Five-year Plan Period”, the National Key Technology R&D Program, and Scientific Special Project of Beijing (Haidian) Municipal Science and Technology Commission, Beijing.</p>"
        },
        {
          "id": 25,
          "active": false,
          "name": "Cao Erbao",
          "title": "Research Director of the Liaison Office of the Central People’s Government in the Hong Kong Special Administrative Region, and Special Researcher of the Counsellors’ Office of the State Council.",
          "desc": "<p>Mr. Cao Erbao is a senior expert on the research of Hong Kong and Macao issues. Since his stay in Hong Kong in 1986, he has participated in the historical process of Hong Kong’s return and the practice of “One Country, Two Systems” after the return. He is familiar with the central government’s policies with respect to Hong Kong, Hong Kong’s political, business and academic circles, and other relevant people. He often gives lectures to the central and mainland departments in connection with Hong Kong, visiting delegations, Chinese enterprises, patriotic organizations, etc., and makes public speeches, publishes articles, and holds talks with the opposition in Hong Kong, all giving a great and positive impact.</p>"
        },
        {
          "id": 27,
          "active": false,
          "name": "Ir Professor Ping-kong Alexander Wai",
          "title": "Fellow of IEEE, Fellow of Optical Society of America, Fellow of the Hong Kong Academy of Engineering Science",
          "desc": "<p>Ir Professor Ping-kong Alexander Wai ( Fellow of IEEE, Fellow of Optical Society of America, Fellow of the Hong Kong Academy of Engineering Science) is Vice President (Research Development) of The Hong Kong Polytechnic University (PolyU). Professor Wai has been selected for the 'National Science and Technology Programmes Expert Database' since February 2012. Professor Wai has over 160 refereed international journal publications. He has participated in the organisation of many international conferences in photonics and optical communications such as the Conference of Laser and Electro-Optics and the Optical Fiber Communication Conference. Professor Wai is currently an Associate Editor of IEEE Journal of Lightwave Technology.</p><p>Nonlinear Optics, Fiber Lasers, Fiber Optic Communications, and Network Theory</p>"
        },
        {
          "id": 9,
          "active": false,
          "name": "Jean-Pierre Cazenave",
          "title": "Honorary Professor of Hematology and Transfusion at the University of Strasbourg",
          "desc": "<p>Honorary Professor of Hematology and Transfusion at the University of Strasbourg, Jean-Pierre Cazenave is also president of the Strasbourg medical research association ARMESA, president of the strategic committee of Health & Biotech France, and permanent member of the French National Academy of Medicine. From 1987 to 2013, he held the position of director at the Blood Transfusion Center EFS-Alsace in Strasbourg. Former president (1992-1995) and vice-president (2002-2010) of the Société Française de Transfusion Sanguine, he is currently member of several international medical societies and author of 620 scientific publications.</p>"
        }
      ]
    }
  ]
}
